RxDoctor Payments Data

Michael Cao, MD

Cardiovascular Disease · Rosemead, CANPI 1548488877

Payments from drug & device makers

$26,270in general payments, 2019–2025

Across 103 payments — averaging $255.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$16K
  • Boston Scientific$7K
  • Medtronic$1K
  • Novartis$1K
  • Galderma Laboratories, L.p.$522
  • Amgen$168
  • plus $363 from 9 others

What the payments were for

  • Speaking & faculty fees$19,30073%
  • Travel & lodging$1,9297%
  • Food & beverage$4,90119%
  • Education$1401%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,270 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$354,477
Medicare patients
991
Services billed
3,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban423$318,079
EntrestoSacubitril/Valsartan176$147,504
EliquisApixaban165$130,573
BrilintaTicagrelor80$40,088
MultaqDronedarone Hcl39$39,451
VascepaIcosapent Ethyl126$26,783
Amiodarone Hcl200$9,984
Ranolazine ErRanolazine190$8,335
Icosapent Ethyl45$6,946
Isosorbide Dinitrate159$5,383
Metoprolol Succinate407$4,786
Atorvastatin Calcium723$4,558
Hydralazine Hcl366$3,072
Nifedipine ErNifedipine171$2,844
PradaxaDabigatran Etexilate Mesylate12$2,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$15,693$318,079423 claims
NovartisEntresto$1,003$147,504176 claims
PfizerEliquis$21$130,573165 claims
AstraZenecaBrilinta$24$40,08880 claims
Sanofi-aventis U.S. LLCMultaq$58$39,45139 claims
Boehringer IngelheimPradaxa$125$2,80012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Rosemead

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →